Moderna (MRNA) Invested Capital (2019 - 2026)

Moderna (MRNA) has 8 years of Invested Capital data on file, last reported at $44.0 million in Q1 2026.

• On a quarterly basis, Invested Capital fell 30.16% year-over-year to $44.0 million in Q1 2026; TTM through Mar 2026 was $205.0 million, a 84.88% decrease from a year earlier, with the FY2025 full-year figure at $45.0 million, down 27.42% from the prior year.
• Invested Capital for Q1 2026 stood at $44.0 million, down from $45.0 million in the prior quarter.
• Over the last five years, Invested Capital for MRNA reached as high as $1.1 billion in Q3 2022 and fell as low as $44.0 million in Q1 2026.
• Historically, Invested Capital has averaged $543.4 million across 5 years, with a median of $576.0 million in 2024.
• Across the five-year window, Invested Capital soared 340.44% in 2022 and slumped 91.3% in 2025, its largest moves.
• Year by year, Invested Capital stood at $1.1 billion in 2022, then sank by 46.41% to $575.0 million in 2023, then plunged by 89.22% to $62.0 million in 2024, then declined by 27.42% to $45.0 million in 2025, then retreated by 2.22% to $44.0 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $44.0 million in Q1 2026, $45.0 million in Q4 2025, and $57.0 million in Q3 2025.